<DOC>
	<DOCNO>NCT00004286</DOCNO>
	<brief_summary>OBJECTIVES : I . Compare evaluate response treatment intravenous human immune globulin ( IVIG ) placebo previously untreated patient chronic inflammatory demyelinate polyneuropathy .</brief_summary>
	<brief_title>Phase III Multicenter Double Blind Controlled Trial Human Immune Globulin Therapy Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This double blind , randomize , control study . Patients receive either intravenous human immune globulin ( IVIG ) placebo infuse rate 40 mL/hr , increase every 30 min maximum 100 mL/hr daily 6 8 hour 2 day . On day 2 , infusion IVIG placebo deliver high dose tolerate day 1 . On day 21 , patient receive another IVIG placebo infusion . Following day 42 , patient may choose continue infusion IVIG every 21 day 2 dos . Patients receive additional treatment release study . Patients evaluate day 10 , 21 , 43 .</detailed_description>
	<mesh_term>Polyradiculoneuropathy</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Chronic inflammatory demyelinate polyneuropathy ( CIDP ) characterize : Progressive relapse disease chronic stable course elevate cerebrospinal fluid protein normal cell count Acquired demyelination electrophysiologic study Segmental demyelination nerve histology Patient Characteristics Not pregnant No significant medical disorder</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>demyelinate neuropathy</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>